22:41 , Jul 30, 2018 |  BC Extra  |  Company News

Management Tracks: Abeona, BioDelivery

Gene therapy play Abeona Therapeutics Inc. (NASDAQ:ABEO) hired Max Colao as chief commercial officer. He was SVP of U.S. commercial operations at Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Allergy company DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) hired Kevin...
00:53 , Jun 3, 2016 |  BC Extra  |  Company News

AstraZeneca continues to divest Zurampic rights

AstraZeneca plc (LSE:AZN; NYSE:AZN) said it granted Gruenenthal Group (Aachen, Germany) exclusive rights to gout drug Zurampic lesinurad in Europe and Latin America. AZ is eligible for $230 million in sales and other milestones, plus...
07:00 , May 2, 2016 |  BioCentury  |  Finance

Playing the primaries

When Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) set out to add to another primary care product, the biotech expected it would likely get a drug nearing the end of its revenue cycle. Instead Ironwood expects newly acquired...
07:00 , May 2, 2016 |  BC Week In Review  |  Company News

AstraZeneca, Ironwood deal

AstraZeneca granted Ironwood exclusive, U.S. rights to Zurampic lesinurad, which FDA approved in December in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout. Ironwood said it plans to launch Zurampic next...
01:14 , Apr 27, 2016 |  BC Extra  |  Company News

Ironwood gets U.S. rights to AZ's Zurampic

AstraZeneca plc (LSE:AZN; NYSE:AZN) granted Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) exclusive, U.S. rights to Zurampic lesinurad , which FDA approved in December in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout (see...
01:15 , Feb 20, 2016 |  BC Extra  |  Company News

AZ's gout drug Zurampic gains EU approval

The European Commission approved an MAA for Zurampic lesinurad from AstraZeneca plc (LSE:AZN; NYSE:AZN) in combination with a xanthine oxidase inhibitor (XOI) to treat hyperuricemia in adults with gout. The company said it will conduct...
01:51 , Dec 23, 2015 |  BC Extra  |  Company News

AZ's Zurampic gains FDA approval for gout

FDA approved Zurampic lesinurad from AstraZeneca plc (LSE:AZN; NYSE:AZN) in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout. The approval came a week ahead of the drug's Dec. 29 PDUFA date....
01:49 , Oct 24, 2015 |  BC Extra  |  Company News

FDA panel backs<span class="*Red-type+bold"> AZ's gout therapy

FDA's Arthritis Advisory Committee voted 10-4 to recommend approval of 200 mg once-daily lesinurad ( RDEA594 ) from AstraZeneca plc (LSE:AZN; NYSE:AZN) in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout....
00:51 , Aug 19, 2015 |  BC Extra  |  Company News

FDA committee to discuss AZ's gout treatment

FDA's Arthritis Advisory Committee will meet on Oct. 23 to discuss an NDA for lesinurad in combination with a xanthine oxidase inhibitor to treat hyperuricemia associated with gout. Ardea Biosciences Inc. submitted the NDA; AstraZeneca...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Conatus management update

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), San Diego, Calif.   Business: Inflammation, Infectious, Endocrine/Metabolic   Hired: David Hagerty as EVP of clinical development, formerly SVP and CMO of Ardea Biosciences Inc. , which AstraZeneca plc acquired  ...